Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Optimized Ultrasound Twinkling Marker Observed for Sonographic Targeting (UTMOST2 Trial)

NCT06999798 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06999798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06999798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study in Patients With Clinically Node-Positive Breast Cancer to Assess the Safety, Ultrasound Conspicuity, and Migration of an Optimized Ultrasound Twinkling Marker Observed for Sonographic Targeting (UTMOST2 Trial)
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
August 29, 2025
Completion date
November 30, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, locally advanced breast carcinoma